Clarkston Capital Partners LLC Has $63.28 Million Stake in Medpace Holdings, Inc. $MEDP

Clarkston Capital Partners LLC trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.8% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 123,064 shares of the company’s stock after selling 6,195 shares during the quarter. Medpace accounts for 1.4% of Clarkston Capital Partners LLC’s holdings, making the stock its 26th biggest position. Clarkston Capital Partners LLC’s holdings in Medpace were worth $63,275,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. lifted its stake in Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares in the last quarter. AQR Capital Management LLC boosted its position in Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after acquiring an additional 81,637 shares during the last quarter. Baillie Gifford & Co. boosted its position in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its stake in shares of Medpace by 11.4% during the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after acquiring an additional 45,435 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP stock opened at $470.59 on Monday. The company has a market capitalization of $13.36 billion, a price-to-earnings ratio of 30.76, a PEG ratio of 2.26 and a beta of 1.44. The company has a 50-day simple moving average of $533.94 and a 200 day simple moving average of $539.47. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period last year, the firm posted $3.67 EPS. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MEDP shares. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a research note on Friday. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Finally, Leerink Partners dropped their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.